Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.

NCT00420316 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1613

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Rotavirus

Interventions

BIOLOGICAL: Rotarix (primary vaccination study)
BIOLOGICAL: Placebo (primary vaccination study)

Sponsor

GlaxoSmithKline